Precirix NV raises €80m in Series B financing
With €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
Sanofi bags €300m from US investor Blackstone
Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Life-sciences hub Saxony: a driver of innovation for cell and gene therapy
Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022
Join 900 US CEOs protest against Ukraine invasion
US Life Science leaders pledge to economically disengage from Russia.
Scenic Biotech BV announces $31m financing
Scenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease.
·
Kurma Partners closes growth fund at €160m
French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m.
mRNA for Africa
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
Epsilogen raise £30.75m in Series B financing
IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
Syndesi swallowed by Abbvie
AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Chinese Huadong snaps up Heidelberg Pharma.
ADC manufacturer Heidelberg Pharma AG has negotiated a US$931m licensing and investment deal with China’s Huadong Medicine Co, Ltd.
The German inventor of alpha-amanitin antibody conjugates (ATACs) will receive an upfront payment of US$20m and milestone payments of up to US$449m related to its phase 1 multiple myeloma candidate HDP-101 and preclinical prostate cancer ATAC HDP-103, as well as royalties on sales of an undisclosed amount. However, the development partnership also covers two further candidates in early preclinical development as well as options on candidates yet to be generated, which are linked to milestone payments of a further USD 461 million. After a long period of waiting, Heidelberg Pharma has thus achieved a breakthrough in the partnering of Amanitin-coupled antibody technology.
In addition to in-licensing the pipeline, Huadong is taking a 35% or €105 million stake in Heidelberg Pharma, which is funded by dievini Holdung. Huadong will enroll Asian patients in global clinical trials to accelerate product development.